Sunshine Biopharma Inc. (SBFM) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on February 20, 2026, reporting events occurring on February 18, 2026. Sunshine Biopharma Inc. is a Colorado corporation with principal executive offices in Fort Lauderdale, Florida. The company's common stock (SBFM) and warrants (SBFMW) trade on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate governance action rather than financial performance.
Material Changes and Corporate Actions
- Reverse Stock Split Authorization: On February 18, 2026, the Company's board of directors was authorized to effect a reverse split of issued and outstanding common stock.
- Split Ratio: The authorized ratio is up to 1-for-10. The board retains discretion on whether to proceed and the exact whole number ratio.
- Voting Mechanism: The action was approved via written consent by Dr. Steve N. Slilaty, the Chief Executive Officer.
- Shareholder Concentration: Dr. Slilaty holds approximately 96% of the total voting power of the Company's stockholders.
- Effectiveness: The shareholder consent will become effective 20 days after the definitive information statement is mailed to stockholders.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future operations, or specific risk factors beyond the implications of the proposed reverse split. The primary contingency is the board's future decision on the exact split ratio and the mailing of the information statement.
Investor Verification Checklist
- Verify the mailing date of the definitive information statement to calculate the exact effective date of the reverse split.
- Monitor subsequent filings for the board's final decision on the specific reverse split ratio (1-for-1 to 1-for-10).
- Confirm the impact of the reverse split on the trading status of SBFM and SBFMW on Nasdaq.
- Review the concentration of ownership (96% held by CEO) regarding potential conflicts of interest in future corporate actions.